Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an update.
Paul Rennie, a significant shareholder in Paradigm Biopharmaceuticals, has ceased to be a substantial holder as of October 30, 2025, due to dilution from the conversion of convertible notes. This change affects over 20 million ordinary shares, impacting the company’s shareholder structure and potentially its market positioning.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for inflammatory diseases. The company is known for its work on repurposing existing drugs to treat new indications, particularly in the area of musculoskeletal disorders.
Average Trading Volume: 1,120,886
Technical Sentiment Signal: Buy
Current Market Cap: A$150M
Learn more about PAR stock on TipRanks’ Stock Analysis page.